Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för azd-7648. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

9 träffar

Bibliografisk träff 2024-07-15

Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.

Hong CR, Liew LP, Wong WW, Dickson BD, Cheng G, Shome A, Airey R, Jaiswal J, Lipert B, Jamieson SMF, Wilson WR, Hay MP.

J Med Chem · research support, non-u.s. gov't; research-article; journal article · DOI 10.1021/acs.jmedchem.4c01120

Bibliografisk träff 2024-04-08

Discovery of Novel Heterotricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer Immunotherapy.

Cheng B, Shi Y, Shao C, Wang S, Su Z, Liu J, Zhou Y, Fei X, Pan W, Chen J, Lu Y, Xiao J.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c02231

Bibliografisk träff 2023-12-20

Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of Malignancies.

Liu K, Yuan X, Yang T, Deng D, Chen Y, Tang M, Zhang C, Zou Y, Zhang S, Li D, Shi M, Guo Y, Zhou Y, Zhao M, Yang Z, Chen L.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.3c01338

Bibliografisk träff 2022-11-08

Phenotypic Discovery of Triazolo[1,5-c]quinazolines as a First-In-Class Bone Morphogenetic Protein Amplifier Chemotype.

Wesseler F, Lohmann S, Riege D, Halver J, Roth A, Pichlo C, Weber S, Takamiya M, Müller E, Ketzel J, Flegel J, Gihring A, Rastegar S, Bertrand J, Baumann U, Knippschild U, Peifer C, Sievers S, Waldmann H, Schade D.

J Med Chem · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.jmedchem.2c01199

Bibliografisk träff 2022-07-07

Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK.

Goldberg FW, Ting AKT, Beattie D, Lamont GM, Fallan C, Finlay MRV, Williamson B, Schimpl M, Harmer AR, Adeyemi OB, Nordell P, Cronin AS, Vazquez-Chantada M, Barratt D, Ramos-Montoya A, Cadogan EB, Davies BR.

ACS Med Chem Lett · rapid-communication; journal article · DOI 10.1021/acsmedchemlett.2c00172

Bibliografisk träff 2022-04-20

Discovery of novel 7,8-dihydropteridine-6(5H)-one-based DNA-PK inhibitors as potential anticancer agents via scaffold hopping strategy.

Ding Z, Pan W, Xiao Y, Cheng B, Huang G, Chen J.

Eur J Med Chem · journal article · DOI 10.1016/j.ejmech.2022.114401

Bibliografisk träff 2022-01-12

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.

Cheng B, Pan W, Xing Y, Xiao Y, Chen J, Xu Z.

Eur J Med Chem · review; journal article · DOI 10.1016/j.ejmech.2022.114109

Bibliografisk träff 2020-11-02

Synthetic Lethality through the Lens of Medicinal Chemistry.

Myers SH, Ortega JA, Cavalli A.

J Med Chem · research support, non-u.s. gov't; review-article; review; journal article · DOI 10.1021/acs.jmedchem.0c00766

Bibliografisk träff 2020-01-15

The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor.

Goldberg FW, Finlay MRV, Ting AKT, Beattie D, Lamont GM, Fallan C, Wrigley GL, Schimpl M, Howard MR, Williamson B, Vazquez-Chantada M, Barratt DG, Davies BR, Cadogan EB, Ramos-Montoya A, Dean E.

J Med Chem · news · DOI 10.1021/acs.jmedchem.9b01684

Gå till forskningen.

Publikationer i urvalet

Identification of 6-Anilino Imidazo[4,5-<i>c</i>]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers.

Discovery of Novel Heterotricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer Immunotherapy.

Discovery, Optimization, and Evaluation of Potent and Selective DNA-PK Inhibitors in Combination with Chemotherapy or Radiotherapy for the Treatment of Malignancies.

Phenotypic Discovery of Triazolo[1,5-<i>c</i>]quinazolines as a First-In-Class Bone Morphogenetic Protein Amplifier Chemotype.

Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8<i>H</i>-purin-8-one Inhibitors of DNA-PK.

Discovery of novel 7,8-dihydropteridine-6(5H)-one-based DNA-PK inhibitors as potential anticancer agents via scaffold hopping strategy.

Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.

Synthetic Lethality through the Lens of Medicinal Chemistry.

The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-<i>a</i>]pyridin-6-yl)amino]-9-(tetrahydro-2<i>H</i>-pyran-4-yl)-7,9-dihydro-8<i>H</i>-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor.